← Back to Search

Antioxidant

treatment for Age-Related Macular Degeneration

Phase < 1
Waitlist Available
Led By Yekaterina Joltikov, MD
Research Sponsored by University of Illinois at Chicago
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age > 50 years old BCVA 20/20 to 20/400 Dry AMD with many large (>300 μm in diameter and more than 100 μm in height) soft drusenoid PEDs
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, 3month, 6month, 12 month timepoints
Awards & highlights

Study Summary

This study is evaluating whether a natural antioxidant may help slow the progression of dry age related macular degeneration.

Eligible Conditions
  • Age-Related Macular Degeneration

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, 3month, 6month, 12 month timepoints
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, 3month, 6month, 12 month timepoints for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Drusen volume
Secondary outcome measures
Drusen size

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: treatmentExperimental Treatment1 Intervention
Group II: controlPlacebo Group1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Curcumin
FDA approved

Find a Location

Who is running the clinical trial?

Illinois Society for the Prevention of BlindnessUNKNOWN
University of Illinois at ChicagoLead Sponsor
609 Previous Clinical Trials
1,559,299 Total Patients Enrolled
VitreoRetinal Surgery FoundationUNKNOWN

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Effect of Oral Curcumin Supplementation in Dry Age-related Macular Degeneration (AMD) Patients
Yekaterina Joltikov 2020. "Effect of Oral Curcumin Supplementation in Dry Age-related Macular Degeneration (AMD) Patients". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04590196.
~2 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top